News

A survey from Vizient of CMS previews reports from member hospitals. Here are the findings.

To generate leads, convert prospects and keep members engaged, health plans must employ a high-touch, multi-channel healthcare marketing strategy which will be much more effective and enroll members who may have not otherwise done so.

Merck’s Wall Street value is climbing after its cancer drug pembrolizumab (Keytruda) received yet another approval from FDA.

New NCCN guidelines include new technology as an option for patients’ annual screening.

Many healthcare organizations lack the necessary governance principles, guidelines, and processes necessary for success in today’s technology-dependent environment.

For healthcare organizations, now is the time to help address Zika fears by utilizing digital tools.

What has you counting sheep at night? Answers from your peers may surprise you.

When Express Scripts and CVS Health announced their 2017 formularies on August 1, a common theme emerged among the healthcare giants: several blockbuster drugs will be removed from both companies’ formularies and lower-cost options such as biosimilars are being embraced.

Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments.

Doctors in these states are now eligible for CPC+. Experts share how to prepare.

Below are some perspectives on what these complaints mean for the parties’ chances and for consolidation in healthcare more generally.

Now a little more than halfway through 2016, it’s time to look at trends in the industry and how they will shape the relationships among stakeholders for the years to come.

As ACOs continue to grow in the healthcare sector, it is imperative that a liaison is in place to act as an intermediary between ACO members and patients to help achieve desired outcomes.

This May, CMS published a final rule addressing Medicaid managed care, through which the regulatory requirements for both the Medicaid MCOs and for states managing the plans has become even more complex.

Risk adjustment has great potential if you follow these three simple rules.

As hospitals begin to search for key post-acute providers and implement new care pathways, providers should be aware of program waivers that afford greater flexibility in determining the most cost-effective care possible to ensure good outcomes for patients within the CJR model.

How one health system and one health plan are fighting the obesity epidemic

AHIP’s president and CEO Marilyn Tavenner discusses the association’s top priorities, challenges, and opportunities.

A senator is investigating whether Medicare's prescription drug benefit is vulnerable to manipulation by pharmaceutical companies after an exclusive Associated Press report showed that Medicare’s spending on certain drugs soared by 85 percent.

Experts break down the controversy over the agency’s release of Overall Hospital Quality Star Ratings.

Obesity and associated comorbidities strain the healthcare system, so why has R&D for new weight loss medications been lackluster?

Are you tracking your prospective pharmacy partners to measure their potential impact on your Star Rating? You should be.

Surveys conducted by the AACE with support from Sanofi US, identified differences in perceptions among adults living with type 2 diabetes. What healthcare professionals don't know may surprise you.

The standard of care for patients unable to drain their bladder is catheter use, but new alternatives reduce risk of antibiotic-resistant superbugs and costs to the healthcare system.

As the 2016 presidential election approaches, analysts and experts are advising healthcare executives to watch and monitor certain issues.

Health insurers and providers are looking for ways to grow outside of the United States. Here’s a look at some of the tactics that are picking up traction.

FDA added new safety labeling changes for a class of antibiotics, fluoroquinolones (Levaquin, Cipro and other branded drugs), to enhance warnings about their association with disabling and potentially permanent side effects. Plus, the new labeling says that the drugs’ use should be limited in patients with less serious bacterial infections.

FDA approved lixisenatide (Adlyxin, Sanofi-Aventis), a once-daily mealtime GLP-1 receptor agonist injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity, Eli Lilly) and the injectable liraglutide (Victoza, Novo Nordisk).

Mayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets.

A large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.